EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

辉瑞(PFE.US)盘前一度涨3.87%至24.44美元。消息面上，辉瑞制药第二季度营收146.5亿美元，同比增长 10%，超过市场预期；调整后每股收益0.78美元，同比增长30%。公司预计全年调整后每股收益2.90美 元至3.10美元，并预测全年营收610亿美元至640亿美元。 ...

Pfizer raises its profit forecast for the year as the drugmaker’s ongoing cost cuts helped make up for a lack of sales growth https://t.co/L6VAlR9ssD ...

Exhibit 99 Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance NEW YORK, Tuesday, August 5, 2025 — Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance for Adjusted diluted EPS. (1) (2) EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "Pfizer had another strong quarter of focused execution and we're pleased with our progress in advancing our R&D pipeline, driving our com ...

格隆汇8月5日｜辉瑞制药第二季度营收146.5亿美元，超过市场预期。辉瑞预计全年调整后每股收益2.90 美元至3.10美元，并预测全年营收610亿美元至640亿美元。 ...

Core Insights - Pfizer raised its full-year adjusted profit guidance due to cost cuts and strong business performance in 2023 [1] - The company reported second-quarter results that exceeded Wall Street's expectations [1] Financial Performance - Adjusted earnings per share were 78 cents, surpassing the expected 58 cents [3] - Revenue for the second quarter was $14.65 billion, compared to the expected $13.56 billion [3] Cost-Cutting Initiatives - Pfizer expanded its cost-cutting efforts in April, aiming for approximately $7.7 billion in savings by the end of 2027 from two separate programs [1] - The company anticipates $150 million in costs related to existing tariffs from President Trump's administration, which were included in its 2025 guidance [2]

市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何 意见、观点或结论是否符合其特定状况。据此投资，责任自负。 辉瑞制药第二季度调整后每股收益0.78美元。辉瑞制药预计全年调整后每股收益2.90美元至3.10美元； 仍然预测全年营收610亿美元至640亿美元。 风险提示及免责条款 ...

Three time-tested companies with rock-solid payouts can pad investors' pocketbooks for a long time to come. Over the last century, no asset class has generated a higher average annualized return for investors than stocks. Though there are countless way for investors to put their money to work on Wall Street, few have been as historically successful as buying and holding high-quality dividend stocks. Companies that pay a regular dividend to their shareholders typically check all the right boxes. Specifically ...

Industry Overview - The second-quarter earnings season for the drug and biotech sector is in full swing, with major companies like Pfizer, Eli Lilly, Amgen, Gilead Sciences, and Novo Nordisk set to announce results [1] - The earnings season began mid-July with Johnson & Johnson reporting strong results, exceeding estimates for both earnings and sales [1] Company Performance Pfizer (PFE) - Pfizer has consistently exceeded earnings expectations in the last four quarters, with an average earnings surprise of 43.49% [6] - The Zacks Consensus Estimate for second-quarter sales and earnings is $13.78 billion and 58 cents per share, respectively [6] - Higher sales from products like Vyndaqel and Padcev are expected to offset weaker sales from Prevnar and Ibrance [8] Eli Lilly (LLY) - Eli Lilly's performance has been mixed, exceeding earnings expectations in two of the last four quarters, with an average earnings surprise of 6.69% [11] - The Zacks Consensus Estimate for second-quarter sales and earnings stands at $14.75 billion and $5.61 per share, respectively [11] - Strong demand for Mounjaro and Zepbound is anticipated to drive top-line growth [12] Amgen (AMGN) - Amgen has shown strong performance, beating earnings estimates in each of the last four quarters, with an average earnings surprise of 8.34% [14] - The Zacks Consensus Estimate for second-quarter sales and earnings is $8.86 billion and $5.26 per share, respectively [14] - Sales growth is expected to be driven by products like Evenity and Repatha, despite price declines due to higher rebates [15] Gilead Sciences (GILD) - Gilead's performance has been mixed, with earnings beating estimates in three of the last four quarters, averaging a surprise of 16.48% [17] - The Zacks Consensus Estimate for second-quarter sales and earnings is $6.95 billion and $1.95 per share, respectively [17] - Increased demand for HIV therapies like Biktarvy is expected to boost sales [18] Novo Nordisk (NVO) - Novo Nordisk's performance has been mixed, with earnings beating estimates in one of the last four quarters, delivering an average surprise of 0.02% [20] - The Zacks Consensus Estimate for second-quarter sales and earnings is $11.79 billion and 93 cents per share, respectively [20] - The company lowered its 2025 sales and operating profit growth outlook due to weaker momentum in key markets for its semaglutide-based drugs [21]

Group 1 - Pfizer's stock has underperformed compared to the broader market since the previous analysis, but total return since mid-May has been positive, indicating that the bearish thesis did not develop as expected [1] - The company is facing a patent cliff, which could impact its future performance [1] Group 2 - The author has a background in IT and has been managing a family portfolio for seven years, gaining confidence in investment decisions through fundamental analysis [1] - The insights shared aim to be accessible for investors of all experience levels, focusing on diverse sectors and uncovering promising prospects [1]